Sep. 9, 2016—Vanderbilt researchers developed a new algorithm to find clinically targetable gene rearrangements in cancers.
Aug. 31, 2016—The sphere-forming frequency of neuroblastoma cells is a measure of their proliferative capacity and could help guide treatment strategies for neuroblastoma.
Aug. 26, 2016—Vanderbilt investigators have demonstrated that a certain protein complex drives tumor progression in aggressive breast cancers.
Jun. 22, 2016—Christine Lovly, M.D., Ph.D., assistant professor of Medicine and Cancer Biology, has been selected to testify before members of Congress about the importance of cancer research, including early training programs for individuals interested in science.
Jun. 6, 2016—New findings identify isoketal-modified proteins as a previously unrecognized feature of pulmonary fibrosis and as a potential therapeutic target for this disease.
May. 12, 2016—Craig Thompson, M.D., president and CEO of Memorial Sloan Kettering Cancer Center, spoke about his lab’s research linking metabolism to stem cell maintenance during his recent Flexner Discovery Lecture.
May. 5, 2016—The primary method used to test compounds for anti-cancer activity in cells is flawed, Vanderbilt University researchers reported May 2 in Nature Methods.
May. 3, 2016—Vanderbilt researchers have discovered that activation of a certain signaling pathway protects brain cancers from targeted therapies, suggesting that using therapeutics that block both pathways may be a promising treatment.
Apr. 28, 2016—A genetic mutation that promotes cancer development blocks the normal sorting of a protein called “Argonaute 2.”
Apr. 28, 2016—Craig Thompson, M.D., president and CEO of Memorial Sloan Kettering Cancer Center, will deliver the next Flexner Discovery Lecture on May 5.
Apr. 1, 2016—The p73 gene is required for the generation of cilia – hair-like projections on cells – findings that could have implications for the study of lung diseases and sterility.
Mar. 3, 2016—Melanoma-specific expression of a certain protein identifies tumors that are more responsive to an immune therapy.